![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Medtronic Receives FDA Clearance for MR-Conditional Quadripolar Cardiac Resynchronization Therapy-Pacemakers
Medtronic Receives FDA Clearance for MR-Conditional Quadripolar Cardiac Resynchronization Therapy-Pacemakers
![](https://www.fdanews.com/ext/resources/test/Device_Images2/Medtronic_Logo.gif?t=1433877334&width=430)
Medtronic has received FDA marketing clearance for a portfolio of quadripolar cardiac resynchronization therapy-pacemakers (CRT-Ps) that improve therapy delivery for patients with heart failure.
The CRT-P portfolio received a CE mark in February 2017.
The Percepta Quad CRT-P MRI SureScan, Serena Quad CRT-P MRI SureScan and Solara Quad CRT-P MRI SureScan are expected to be available in the U.S. in early summer 2017. — Cynthia Jessup
Upcoming Events
-
21Oct